NCT07088913View on ClinicalTrials.gov

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2025

Conditions

Healthy Participants

Interventions

DRUG

Capivasertib

Capivasertib will be administered orally twice in Period 2.

DRUG

Rosuvastatin

Rosuvastatin will be administered orally once in both Period 1 and Period 2.

Trial Locations (1)

21225

RECRUITING

Research Site, Baltimore

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY